BACK TO CONTENTS   |    PDF   |    NEXT

Title

 

 

 

 

 

The expanding HIV-1 epidemic aggravates therapeutics and vaccine development programs in India

Authors

 

Ujjwal Neogi

Affiliation

 

Infectious Disease Unit, St. Johnís Research Institute, Koramangla, Bangalore-560034

Email

 

ujjwalneogi@gmail.com

Article Type

 

Views & Challenges

Date

 

Received July 10, 2009; Accepted July 25, 2009; Published September 30, 2009

Abstract

Human Immunodeficiency Virus Type 1 (HIV-1) displays extensive genetic diversity globally that poses a serious challenge in designing suitable therapeutic measures for protective immune responses in the host. After the first detection of AIDS cases in 1986, India now has the third largest HIV epidemic in world. The HIV-1 epidemic in India is still growing with introduction of new strains/subtypes and this creates a serious problem for the clinician and basic science researchers to find the effective measures. Neighboring countries in the North and North-eastern regions play an important role in the HIV-1 pandemic. An extensive multinational collaborative research effort is needed in order to identify the risk groups and geographic locales is required to monitor HIV-1 spread in Asia and to produce a successful preventive program.

 

Keywords

HIV-1 Epidemiology, India, Asia, vaccine, therapeutics, co-operation

 

Citation

 

Neogi, Bioinformation 4(3): 90-91 (2009)

Edited by

 

P. Kangueane

 

ISSN

 

0973-2063

 

Publisher

 

Biomedical Informatics

License

 

 

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.